Add BrightSurf on Google Email

Herpes medication does not reduce risk of HIV transmission, UW-led international study finds

A five-year international study found that acyclovir suppressive therapy did not reduce the risk of HIV transmission in couples where one partner had both HIV and HSV-2. The study revealed significant reductions in plasma HIV levels and genital ulcers, but no impact on HIV transmission.

SourceUniversity of Washington School of Medicine/UW Medicine·JournalNew England Journal of Medicine·DateJan 20, 2010

Each pound at birth lowers risk of developing TB

A study published in the Journal of Infectious Diseases found that each additional 1.1 pounds of birth weight decreases tuberculosis risk by 46% among identical twins. The association is stronger for males, with an 87% reduced risk, and sheds light on the developmental origins of health and disease.

SourceUniversity of Michigan·JournalThe Journal of Infectious Diseases·DateJan 7, 2010

Tuberculosis: On the path to prevention

Scientists at MUHC and international colleagues discovered a chromosomal site controlling natural resistance to TB infection, found in 20% of individuals from high-exposure areas. The findings hold promise for preventing TB infection in the general population by stimulating resistance mechanisms.

SourceMcGill University Health Centre·JournalJournal of Experimental Medicine·DateNov 30, 2009

A reductionist approach to HIV research

A team of researchers has created a mouse model with key features of HIV infection, shedding light on the disease's mechanisms. The mouse exhibits symptoms similar to those of immunodeficiency virus infection, but with notable differences that highlight its limitations as a model for human disease.

SourceBMC (BioMed Central)·JournalJournal of Biology·DateNov 30, 2009

JCI table of contents: Nov. 23, 2009

A study identified a gene variant associated with elevated baseline blood pressure, suggesting it may be a good target for drugs to alleviate stress-induced hypertension. The researchers also found that the protein generated by this gene influences sympathetic activity and prevents stress-induced hypertension in both mice and humans.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateNov 23, 2009

Why circumcision reduces HIV risk

Male circumcision significantly reduces HIV infection risk by 60% in rural Uganda men. The removal of foreskin tissue containing HIV target cells explains most of the protection. Circumcision also reduces genital ulcer disease by lowering rates of trauma-induced ulcers, not just those caused by herpes.

SourcePLOS·JournalPLOS Medicine·DateNov 23, 2009

Lessons for HIV learned from monkey control of SIV infection

Researchers have discovered that SIV induces a vigorous immune response in both natural and susceptible hosts, but only in natural hosts is the response brought under control. This study provides new insights into how to control HIV infection of humans by understanding the mechanisms behind SIV's rapid control of immune activation.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateNov 23, 2009

An atomic-level look at an HIV accomplice

Scientists at the University of Michigan have determined the atomic-level structure of a SEVI precursor and found it damages cell membranes to make them more vulnerable to HIV infection. The study provides insights into how SEVI interacts with cell membranes, which may help in developing new treatments for AIDS.

SourceUniversity of Michigan·JournalJournal of the American Chemical Society·DateNov 19, 2009

HIV vaccine failure probably caused by virus used, says new research

Researchers found that people who had previously built up immunity to the adenovirus used in the trial had a higher risk of infection with HIV after receiving the vaccine. The study suggests that other adenovirus-based vaccines, such as those for tuberculosis and malaria, may also be at risk due to the same immune system reaction.

SourceImperial College London·JournalProceedings of the National Academy of Sciences·DateNov 16, 2009

Continuing racial differences in HIV prevalence in US

Research found racial differences in individual behaviors do not fully explain marked disparities in HIV infection prevalence. Social factors such as exposure to the virus through racially segregated mixing patterns and poverty contribute to these differences. The US response to the epidemic has failed to control the spread of HIV amon...

SourceElsevier Health Sciences·JournalAmerican Journal of Preventive Medicine·DateOct 6, 2009

JCI online early table of contents: Oct. 1, 2009

Researchers have developed innovative strategies to eliminate the hidden reservoir of HIV-1 from immune cells, keeping it under control. In another breakthrough, scientists found a way to transiently keep hepatitis C virus levels down in treated patients receiving a new liver transplant.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateOct 1, 2009

New approach to targeting the hidden reservoir of HIV

Researchers at Johns Hopkins University have developed an in vitro system to identify compounds that can eliminate HIV-1 from resting CD4+ T cells without causing global T cell activation. This breakthrough offers a potential solution for eliminating the virus's hidden reservoir.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateOct 1, 2009

UAB researchers find TB-prevention therapy is cost-effective option

Researchers at UAB found that preventive antibiotic TB therapy for HIV-infected patients is approximately $950 per case, compared to a previously reported range of $900-$1500 for treating new smear-positive TB cases. The integrated care approach also offers economic benefits by reducing productivity losses and preventing the spread of TB.

SourceUniversity of Alabama at Birmingham·JournalThe International Journal of Tuberculosis and Lung Disease·DateSep 9, 2009

JCI online early table of contents: Sept. 8, 2009

Scientists have engineered a human HIV-1 inhibitor modeled after an owl monkey fusion protein that potently blocks HIV-1 infection. This new treatment showed promise in preventing viral replication in mice and has the potential to be a robust anti-HIV-1 gene therapy candidate.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateSep 8, 2009

HIV subtype linked to increased likelihood for dementia

A new study by Johns Hopkins researchers reveals that HIV subtype D is associated with a significantly higher likelihood of developing dementia. The study found that nearly all (89%) patients infected with subtype D developed dementia, whereas only about 24% of those infected with subtype A showed signs of the condition.

SourceJohns Hopkins Medicine·JournalClinical Infectious Diseases·DateAug 28, 2009

In vitro antibody production enables HIV infection detection in window period -- key to safer blood

Researchers have developed an in-vitro antibody production technique to detect HIV infection earlier, reducing the diagnostic window period. This method promotes the synthesis and release of antibodies against HIV-1 prior to detection in plasma samples, leading to safer blood supply and improved diagnosis.

SourceSociety for Experimental Biology and Medicine·JournalExperimental Biology and Medicine·DateJul 24, 2009

Penn-Wistar team gains insight into HIV vaccine failure

A team of researchers refuted a popular hypothesis about the failure of the Merck STEP HIV vaccine study by finding no correlation between pre-existing neutralizing antibodies and increased susceptibility to infection. The study analyzed blood samples from participants with varying degrees of pre-existing immunity to Ad5 and found that...

SourceThe Wistar Institute·JournalNature Medicine·DateJul 20, 2009

Studies needed on susceptibility of immunosuppressed people to flu and the effects of vaccination

Studies indicate that immunosuppressed populations, including HIV/AIDS patients, cancer patients, transplant recipients, and those on haemodialysis, are at higher risk for flu infection. Vaccination has shown promise in reducing flu cases, but more research is needed to assess vaccine efficacy and timing for optimal protection.

SourceThe Lancet_DELETED·JournalThe Lancet Infectious Diseases·DateJul 20, 2009